found that inhibition of NLRP3, ASC or caspase-1 protects against pancreatic ductal adenocarcinoma (PDA) via immunogenic reprogramming of innate and adaptive immunity within the TME (27). Here, NLRP3 is linked to Patent ductus arteriosus.